Key result
Renal denervation lowers systolic blood pressure by ~42 mmHg at 3 months in ADPKD.
Why the study?
Sympathetic hyperactivity may contribute to hypertension in ADPKD, but data on the effect of renal denervation on sympathetic activity in these patients are lacking.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for renal denervation in ADPKD hypertension; prospective trials needed before clinical adoption.
The underlying mechanisms for the rise in blood pressure in individuals with autosomal dominant polycystic kidney disease (ADPKD) are complex, and experimental and clinical data support the concept that sympathetic hyperactivity may contribute to the pathogenesis of hypertension in ADPKD [1,2].More recently, a catheter-based percutaneous aimed at ablating both efferent and afferent renal nerve fibres has been introduced into clinical medicine and has been demonstrated to safely and effectively reduce blood pressure in patients with treatment resistant hypertension and normal renal function [3][4][5][6].However, to our knowledge there is only one report of Shetty et al. [7] who observed after renal denervation resolution of chronic pain related to renal cysts and delayed fall in blood pressure in patient with ADPKD and resistant to treatment hypertension.No data on reduction of sympathetic activity has been shown.
No takes yet. Share an insight, caveat, or question.
Prejbisz et al. (2013) conducted a case report in Autosomal dominant polycystic kidney disease (ADPKD) and resistant hypertension (n=1). Percutaneous renal sympathetic denervation vs. Baseline (pre-ablation) was evaluated on Change in blood pressure and muscle sympathetic-nerve activity. Percutaneous renal sympathetic denervation reduced office blood pressure from 162/77 mmHg to 120/74 mmHg and decreased muscle sympathetic-nerve activity at 3 months in a patient with ADPKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: